Michael Curry, MD
Hepatology · Boston, MANPI 1518939446
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $83,775 of the $88,505 with a category attached, or 94.7%. Mallinckrodt Hospital Products Inc. accounts for 63.2% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2022 at $36,553 and has fallen 83.9% since, to $5,869 in 2025.
Across 52 payments — averaging $1702.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$56K
- AstraZeneca$13K
- Gilead$8K
- Pfizer$7K
- Albireo Pharma, Inc.$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- plus $486 from 3 others
Across 46 payments — averaging $7977.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$182K
- Mallinckrodt Enterprises LLC$165K
- Intercept Pharmaceuticals, Inc.$17K
- Bausch Health US, LLC$3K
What the payments were for
- Consulting fees$83,77595%
- Travel & lodging$2,9853%
- Food & beverage$1,7452%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 26 | $55,935 |
| AstraZeneca | 7 | $13,401 |
| Gilead | 5 | $8,183 |
| Pfizer | 8 | $7,000 |
| Albireo Pharma, Inc. | 1 | $1,950 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $1,550 |
| Madrigal Pharmaceuticals | 2 | $194 |
| Miach Orthopaedics, Inc. | 1 | $177 |
| Novo Nordisk | 1 | $115 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TERLIVAZ$10,872
- Bylvay$1,950
- XIFAXAN$1,550
- RESMETIROM$146
How this compares
Too few hepatology providers in Massachusettsto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 132 | $429,345 |
| OcalivaObeticholic Acid | 12 | $131,567 |
| RezdiffraResmetirom | 20 | $79,135 |
| VemlidyTenofovir Alafenamide | 34 | $49,593 |
| Ursodiol | 231 | $42,651 |
| OzempicSemaglutide | 31 | $35,019 |
| EliquisApixaban | 17 | $21,489 |
| Entecavir | 26 | $5,059 |
| Tacrolimus | 34 | $4,752 |
| Mycophenolate Mofetil | 25 | $4,287 |
| Azathioprine | 38 | $3,591 |
| Spironolactone | 120 | $2,159 |
| Mycophenolic AcidMycophenolate Sodium | 12 | $1,349 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 20 | $1,299 |
| Lactulose | 54 | $1,279 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $1,550 | $429,345132 claims |
| Madrigal PharmaceuticalsRezdiffra | $194 | $79,13520 claims |
| GileadVemlidy | $8,183 | $49,59334 claims |
| Novo NordiskOzempic | $115 | $35,01931 claims |
| PfizerEliquis | $7,000 | $21,48917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hepatology providers in Massachusettson file to place this against a meaningful peer group, so we don't.
Other hepatology in Boston
- Nezam AfdhalBoston$332K
- Fredric GordonBoston$284K
- Daryl LauBoston$42K
- Zachary FrickerBoston$9K
- Michelle LaiBoston$6K
- Simon RobsonBoston$6K
- Sanjiv ChopraBoston$4K
- Vilas PatwardhanBoston$2K
- Dusanka GrbicBoston$304
- Lauren YangBoston$11
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.